Extract
Pulmonary arterial hypertension (PAH) is a rare disease characterized by remodelling of small pulmonary vessels, which results in a progressive increase in right ventricular afterload [1]. Most of the symptoms and signs of PAH are attributable to impaired right heart function. However, patients with PAH also show variable alterations of their lung diffusion capacity for carbon monoxide (DLCO) and gas exchange which contribute to disease symptoms and severity.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: KM Olsson has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, Ferrer, GSK, Janssen, MSD, Pfizer, and United Therapeutics.
Conflict of interest: J Fuge has received personal fees/speaker honoraria from AstraZeneca outside the submitted work.
Conflict of interest: DH Park is supported by PRACTIS – Clinician Scientist Program at Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3-1).
Conflict of interest: JC Kamp is supported by PRACTIS – Clinician Scientist Program at Hannover Medical School, funded by the German Research Foundation (DFG, ME 3696/3-1).
Conflict of interest: T Brod has no disclosures. B Harrigfeld has no disclosures.
Conflict of interest: JC Schupp has patents on new therapies in pulmonary fibrosis and has received lecture fees from Boehringer Ingelheim.
Conflict of interest: MM Hoeper reports fees for lectures and/or consultations from Acceleron, Actelion, Altavant, AOP Health, Bayer, Ferrer, Janssen and MSD, and has a patent application filed by MSD for US patent application # 63466014, Methods of improving lung diffusion capacity in a patients with pulmonary arterial hypertension.
- Received May 17, 2023.
- Accepted July 8, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions{at}ersnet.org